Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -6,697 | -5,806 | -7,549 | -12,612 |
| Operating lease right-of-use asset | - | - | 148 | 278 |
| Stock-based compensation | 57 | 2 | 77 | 17 |
| Accounts payable, accrued compensation, accrued expenses and other current liabilities, and short-term operating lease | - | 434 | 724 | -1,315 |
| Non-cash lease expense | 271 | 1,089 | - | - |
| Depreciation and amortization | 35 | 81 | 49 | 110 |
| Prepaid expenses and other current assets | -3 | -126 | -83 | -274 |
| Accounts payable | 13 | - | - | - |
| Accrued expenses and other current liabilities | -1,303 | - | - | - |
| Long-term operating lease liability | - | - | -220 | -420 |
| Operating lease liability | -344 | -1,376 | - | - |
| Net cash used in operating activities | -7,965 | -5,236 | -6,688 | -13,668 |
| Net cash from investing activities | 0 | 0 | - | - |
| Value of equity awards withheld for tax liability | - | 0 | - | - |
| Proceeds from exercise of common warrants, net of issuance costs | - | 557 | - | - |
| Proceeds from issuance of common stock, net of issuance costs | 872 | 37,940 | - | - |
| Proceeds from issuance of common stock and pre-funded warrants exercise, net of issuance costs | - | - | - | 14,364 |
| Proceeds from issuance of common stock, pre-funded warrants exercise, and common warrants exercise, net of issuance costs | - | - | 32,703 | - |
| Payments in lieu of fractional shares | 1 | - | - | - |
| Net cash provided by financing activities | 871 | 5,794 | 18,339 | 14,364 |
| Increase (decrease) in cash and cash equivalents | -7,094 | 558 | 11,651 | 696 |
| Cash and cash equivalents at beginning of period | 21,619 | 21,061 | 8,714 | - |
| Cash and cash equivalents at end of period | 14,525 | 21,619 | 21,061 | - |